Chemotherapy Induced Peripheral Neuropathy - Drug Pipeline Landscape, 2023

Chemotherapy Induced Peripheral Neuropathy - Drug Pipeline Landscape, 2023

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment that can cause tingling, numbness, and pain in the hands and feet. CIPN is caused by damage to the nerves that send signals from the body to the brain.

Chemotherapy-induced neuropathy is caused by a substantial number of cytotoxic drugs, including taxanes, platinums, vinca alkaloids, epothilones, eribulin, and bortezomib; these drugs cause different pathologic insults to neurons.

The symptoms of CIPN can range from mild to severe, and they can last for weeks, months, or even years after treatment has ended. There is no cure for CIPN, but there are treatments that can help lessen the symptoms.

There are many companies actively developing chemotherapy induced peripheral neuropathy drugs, including Eisai Co Ltd, Asahi Kasei Pharma Corp, and Advinus Therapeutics Ltd.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Chemotherapy Induced Peripharal Neurophaty treatment such as Nicotinamide Riboside, PSP Neuro Serum, Venlafaxine and others. Key players involved in the development of therapies to treat Chemotherapy Induced Peripharal Neurophaty are Bexion Pharmaceuticals Inc, Eisai Co Ltd, MediciNova, Mendel AI, Novaremed and others. One drug is under late-stage Phase III clinical trials and six drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

Report Highlights

Global Insight Service's, Chemotherapy Induced Peripheral Neuropathy - Drug Pipeline Landscape, 2023 report provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline drugs. This report covers detailed insights on Chemotherapy Induced Peripheral Neuropathy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Chemotherapy Induced Peripheral Neuropathy pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.